Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease

NCT06068465 is registered in ClinicalTrials.gov with Tasly Pharmaceutical Group Co., Ltd as lead sponsor.

NCT NCT06068465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06068465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease
Lead sponsor
Tasly Pharmaceutical Group Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
September 27, 2024
Completion date
February 1, 2026
Enrollment
248 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease psychosis